Boehringer Ingelheim’s signal analytics technology acquired by ArisGlobal

ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment

Boehringer Ingelheim and ArisGlobal, the global market leader in drug safety solutions worldwide announced the acquisition of Boehringer Ingelheim’s digital innovation, BRASS, by ArisGlobal. This data insights engine will be integrated into ArisGlobal’s technology platform, LifeSphere, under the name of LifeSphere Clarity, and will play a key role in driving industry-wide advancement of pharmacovigilance and patient safety.

LifeSphere Clarity is an intelligent signal analytics technology that provides insights which are otherwise challenging or impossible to find. Jointly developed by Boehringer Ingelheim’s Patient Safety and Technology teams, the digital engine leverages automation and artificial intelligence to consolidate patient safety data, reveals possible reasons why things happened, and allows modeling the possible impact of different influences.

Once integrated into the LifeSphere platform, users will be presented with valuable connections and gain deeper insights, faster. Making this tool available within the LifeSphere platform will harness the user community’s input to make better-automated suggestions on possible causal patterns influencing adverse events. Ultimately, this will give the safety specialist user within a pharmaceutical company the ability to create a more efficient medical benefit-risk analysis. This informative technology will advance ArisGlobal’s LifeSphere Data and Analytics initiative, delivering complementary capabilities to LifeSphere Signal and Risk Management as one example of the application for the technology.

“At Boehringer Ingelheim, we always put the patients first. BRASS (soon to become LifeSphere Clarity) is a system that can help a pharmaceutical company understand the whole network of how diseases, comorbidities, effects and side effects of medications, as well as medical events influence each other. The ambition is to ensure that each patient gets the best and safest therapy option for them, and robust and rapid benefit-risk assessment also helps get the right therapies to patients faster,” states Robert Buchberger, Head of Patient Safety & Pharmacovigilance at Boehringer Ingelheim.

“With our deep industry expertise, ArisGlobal is uniquely positioned to synthesize these powerful insights for our life sciences customers,” shares Pat Jenakanandhini, Chief Product Officer at ArisGlobal.

This digital innovation represents impactful progress industry-wide, as it opens an opportunity for many life sciences organizations to advance their pharmacovigilance analytics and insights. It is also representative of the power of partnership across the life sciences industry, as Boehringer Ingelheim and ArisGlobal have worked collaboratively for over three decades, continually striving for, and achieving, pharmacovigilance innovation.